{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T06:51:49Z","timestamp":1776063109643,"version":"3.50.1"},"reference-count":262,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Vice Chancellery for Research of Isfahan University of Medical Sciences","award":["3403273"],"award-info":[{"award-number":["3403273"]}]},{"DOI":"10.13039\/501100003968","name":"Iran National Science Foundation","doi-asserted-by":"publisher","award":["4040702"],"award-info":[{"award-number":["4040702"]}],"id":[{"id":"10.13039\/501100003968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroimmune Pharmacol"],"DOI":"10.1007\/s11481-026-10286-x","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:59:30Z","timestamp":1776059970000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rethinking MS Therapeutics: From Disease Pathogenesis Mechanisms to AI-Driven Drug Discovery"],"prefix":"10.1007","volume":"21","author":[{"given":"Maryam","family":"Ziaei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadreza","family":"Sehhati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadreza","family":"Torabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7237-1984","authenticated-orcid":false,"given":"Nafiseh","family":"Esmaeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9333-4699","authenticated-orcid":false,"given":"Fahimeh","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"10286_CR1","doi-asserted-by":"publisher","first-page":"107715","DOI":"10.1016\/j.intimp.2021.107715","volume":"97","author":"F Abbasirad","year":"2021","unstructured":"Abbasirad F, Shaygannejad V, Hosseininasab F et al (2021) Significant immunomodulatory and hepatoprotective impacts of Silymarin in MS patients: A double-blind placebo-controlled clinical trial. Int Immunopharmacol 97:107715. https:\/\/doi.org\/10.1016\/j.intimp.2021.107715","journal-title":"Int Immunopharmacol"},{"key":"10286_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.34172\/apb.2023.012","volume":"13","author":"AA Alizadeh","year":"2023","unstructured":"Alizadeh AA, Jafari B, Dastmalchi S (2023) Drug repurposing for identification of S1P1 agonists with potential application in multiple sclerosis using in silico drug design approaches. Adv Pharm Bull 13:113\u2013122. https:\/\/doi.org\/10.34172\/apb.2023.012","journal-title":"Adv Pharm Bull"},{"key":"10286_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1212\/01.wnl.0000316802.35974.34","volume":"71","author":"A Alonso","year":"2008","unstructured":"Alonso A, Hern\u00e1n MA (2008) Temporal trends in the incidence of multiple sclerosis. Neurology 71:129\u2013135. https:\/\/doi.org\/10.1212\/01.wnl.0000316802.35974.34","journal-title":"Neurology"},{"key":"10286_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2217\/nmt-2021-0058","volume":"13","author":"M Amin","year":"2023","unstructured":"Amin M, Hersh CM (2023) Updates and advances in multiple sclerosis neurotherapeutics. Neurodegener Dis Manage 13:47\u201370. https:\/\/doi.org\/10.2217\/nmt-2021-0058","journal-title":"Neurodegener Dis Manage"},{"key":"10286_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/07391102.2017.1418679","volume":"37","author":"SA Amin","year":"2019","unstructured":"Amin SA, Adhikari N, Baidya SK et al (2019) Structural refinement and prediction of potential CCR2 antagonists through validated multi-QSAR modeling studies. J Biomol Struct Dynamics 37:75\u201394. https:\/\/doi.org\/10.1080\/07391102.2017.1418679","journal-title":"J Biomol Struct Dynamics"},{"key":"10286_CR6","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00415-023-12132-z","volume":"271","author":"M Andorra","year":"2024","unstructured":"Andorra M, Freire A, Zubizarreta I et al (2024) Predicting disease severity in multiple sclerosis using multimodal data and machine learning. J Neurol 271:1133\u20131149. https:\/\/doi.org\/10.1007\/s00415-023-12132-z","journal-title":"J Neurol"},{"key":"10286_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/cem.3545","author":"N Arabi","year":"2024","unstructured":"Arabi N, Torabi MR, Fassihi A, Ghasemi F (2024) Identification of potential vascular endothelial growth factor receptor inhibitors via tree-based learning modeling and molecular docking simulation. J Chemom. https:\/\/doi.org\/10.1002\/cem.3545","journal-title":"J Chemom"},{"key":"10286_CR8","doi-asserted-by":"publisher","first-page":"14593","DOI":"10.1073\/pnas.0404887101","volume":"101","author":"R Arnon","year":"2004","unstructured":"Arnon R, Aharoni R (2004) Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A 101:14593\u201314598. https:\/\/doi.org\/10.1073\/pnas.0404887101","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10286_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1459502","author":"G Arrambide","year":"2024","unstructured":"Arrambide G, Comabella M, Tur C (2024) Big data and artificial intelligence applied to blood and CSF fluid biomarkers in multiple sclerosis. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2024.1459502","journal-title":"Front Immunol"},{"key":"10286_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.975862","author":"P Ashtari","year":"2022","unstructured":"Ashtari P, Barile B, Van Huffel S, Sappey-Marinier D (2022) New multiple sclerosis lesion segmentation and detection using pre-activation U-Net. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2022.975862","journal-title":"Front Neurosci"},{"key":"10286_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1084\/jem.192.3.393","volume":"192","author":"H Babbe","year":"2000","unstructured":"Babbe H, Roers A, Waisman A et al (2000) Clonal Expansions of Cd8\u2009+\u2009T Cells Dominate the T Cell Infiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction. J Exp Med 192:393\u2013404. https:\/\/doi.org\/10.1084\/jem.192.3.393","journal-title":"J Exp Med"},{"key":"10286_CR12","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.neuron.2018.01.021","volume":"97","author":"C Baecher-Allan","year":"2018","unstructured":"Baecher-Allan C, Kaskow BJ, Weiner HL (2018) Multiple Sclerosis: mechanisms and immunotherapy. Neuron 97:742\u2013768. https:\/\/doi.org\/10.1016\/j.neuron.2018.01.021","journal-title":"Neuron"},{"key":"10286_CR13","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","volume":"74","author":"D Baker","year":"2017","unstructured":"Baker D, Herrod SS, Alvarez-Gonzalez C et al (2017) Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of Alemtuzumab. JAMA Neurol 74:961\u2013969. https:\/\/doi.org\/10.1001\/jamaneurol.2017.0676","journal-title":"JAMA Neurol"},{"key":"10286_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrd.2015.21","volume":"15","author":"WA Banks","year":"2016","unstructured":"Banks WA (2016) From blood\u2013brain barrier to blood\u2013brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov 15:275\u2013292. https:\/\/doi.org\/10.1038\/nrd.2015.21","journal-title":"Nat Rev Drug Discov"},{"key":"10286_CR15","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S1474-4422(21)00063-6","volume":"20","author":"A Bar-Or","year":"2021","unstructured":"Bar-Or A, Li R (2021) Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances. Lancet Neurol 20:470\u2013483. https:\/\/doi.org\/10.1016\/S1474-4422(21)00063-6","journal-title":"Lancet Neurol"},{"key":"10286_CR16","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1093\/brain\/awg285","volume":"126","author":"A Bar-Or","year":"2003","unstructured":"Bar-Or A, Nuttall RK, Duddy M (2003) Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain 126:2738\u20132749. https:\/\/doi.org\/10.1093\/brain\/awg285","journal-title":"Brain"},{"key":"10286_CR17","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000205299","volume":"102","author":"A Bar-Or","year":"2024","unstructured":"Bar-Or A, Dufek M, Budincevic H et al (2024) Impact of Fenebrutinib Treatment on MRI Outcomes and Cerebrospinal Fluid Penetrance in Multiple Sclerosis: Results from the Phase II FENopta Study (S31.004). Neurology 102:3669. https:\/\/doi.org\/10.1212\/WNL.0000000000205299","journal-title":"Neurology"},{"key":"10286_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107562","volume":"95","author":"P Bayat","year":"2021","unstructured":"Bayat P, Farshchi M, Yousefian M et al (2021) Flavonoids, the compounds with anti-inflammatory and immunomodulatory properties, as promising tools in multiple sclerosis (MS) therapy: a systematic review of preclinical evidence. Int Immunopharmacol 95:107562. https:\/\/doi.org\/10.1016\/j.intimp.2021.107562","journal-title":"Int Immunopharmacol"},{"key":"10286_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cells8010024","volume":"8","author":"N Behrangi","year":"2019","unstructured":"Behrangi N, Fischbach F, Kipp M (2019) Mechanism of Siponimod: anti-inflammatory and neuroprotective mode of action. Cells 8:24. https:\/\/doi.org\/10.3390\/cells8010024","journal-title":"Cells"},{"key":"10286_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/neurolint13020022","volume":"13","author":"AA Berger","year":"2021","unstructured":"Berger AA, Sottosanti ER, Winnick A et al (2021) Monomethyl fumarate (MMF, Bafiertam) for the treatment of relapsing forms of multiple sclerosis (MS). Neurol Int 13:207\u2013223. https:\/\/doi.org\/10.3390\/neurolint13020022","journal-title":"Neurol Int"},{"key":"10286_CR21","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.3390\/molecules27196307","volume":"27","author":"SP Bhujbal","year":"2022","unstructured":"Bhujbal SP, He W, Hah J-M (2022) Design of novel IRAK4 inhibitors using molecular docking, dynamics simulation and 3D-QSAR studies. Molecules 27:6307. https:\/\/doi.org\/10.3390\/molecules27196307","journal-title":"Molecules"},{"key":"10286_CR22","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41573-022-00477-5","volume":"21","author":"L Bierhansl","year":"2022","unstructured":"Bierhansl L, Hartung H-P, Aktas O et al (2022) Thinking outside the box: non-canonical targets in multiple sclerosis. Nat Rev Drug Discov 21:578\u2013600. https:\/\/doi.org\/10.1038\/s41573-022-00477-5","journal-title":"Nat Rev Drug Discov"},{"key":"10286_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2022.103065","volume":"35","author":"R Bonacchi","year":"2022","unstructured":"Bonacchi R, Filippi M, Rocca MA (2022) Role of artificial intelligence in MS clinical practice. NeuroImage: Clinical 35:103065. https:\/\/doi.org\/10.1016\/j.nicl.2022.103065","journal-title":"NeuroImage: Clinical"},{"key":"10286_CR24","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s13311-017-0577-0","volume":"14","author":"RM Bove","year":"2017","unstructured":"Bove RM, Green AJ (2017) Remyelinating pharmacotherapies in multiple sclerosis. Neurotherapeutics 14:894\u2013904. https:\/\/doi.org\/10.1007\/s13311-017-0577-0","journal-title":"Neurotherapeutics"},{"key":"10286_CR25","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00401-013-1112-y","volume":"125","author":"A Boyd","year":"2013","unstructured":"Boyd A, Zhang H, Williams A (2013) Insufficient OPC migration into demyelinated lesions is a cause of poor remyelination in MS and mouse models. Acta Neuropathol 125:841\u2013859. https:\/\/doi.org\/10.1007\/s00401-013-1112-y","journal-title":"Acta Neuropathol"},{"key":"10286_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cells11132058","volume":"11","author":"G\u00c1 Bravo","year":"2022","unstructured":"Bravo G\u00c1, Cede\u00f1o RR, Casadevall MP, Rami\u00f3-Torrent\u00e0 L (2022) Sphingosine-1-phosphate (S1P) and S1P signaling pathway modulators, from current insights to future perspectives. Cells 11:2058. https:\/\/doi.org\/10.3390\/cells11132058","journal-title":"Cells"},{"key":"10286_CR27","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.cell.2019.09.035","volume":"179","author":"CC Brown","year":"2019","unstructured":"Brown CC, Gudjonson H, Pritykin Y et al (2019) Transcriptional basis of mouse and human dendritic cell heterogeneity. Cell 179:846-863.e24. https:\/\/doi.org\/10.1016\/j.cell.2019.09.035","journal-title":"Cell"},{"key":"10286_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac153","volume":"4","author":"T Brummer","year":"2022","unstructured":"Brummer T, Muthuraman M, Steffen F et al (2022) Improved prediction of early cognitive impairment in multiple sclerosis combining blood and imaging biomarkers. Brain Commun 4:fcac153. https:\/\/doi.org\/10.1093\/braincomms\/fcac153","journal-title":"Brain Commun"},{"key":"10286_CR29","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/1873-3468.13013","volume":"592","author":"G Campbell","year":"2018","unstructured":"Campbell G, Mahad DJ (2018) Mitochondrial dysfunction and axon degeneration in progressive multiple sclerosis. FEBS Lett 592:1113\u20131121. https:\/\/doi.org\/10.1002\/1873-3468.13013","journal-title":"FEBS Lett"},{"key":"10286_CR30","doi-asserted-by":"publisher","first-page":"820","DOI":"10.4049\/jimmunol.2100977","volume":"209","author":"R Cao","year":"2022","unstructured":"Cao R, Li Z, Wu C et al (2022) Identification of a small molecule with strong anti-inflammatory activity in experimental autoimmune encephalomyelitis and sepsis through blocking Gasdermin D activation. J Immunol 209:820\u2013828. https:\/\/doi.org\/10.4049\/jimmunol.2100977","journal-title":"J Immunol"},{"key":"10286_CR31","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/S0140-6736(25)01039-6","volume":"406","author":"J Chataway","year":"2025","unstructured":"Chataway J, Williams T, Blackstone J et al (2025) Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 406:1611\u20131624. https:\/\/doi.org\/10.1016\/S0140-6736(25)01039-6","journal-title":"Lancet"},{"key":"10286_CR32","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.drudis.2018.01.039","volume":"23","author":"H Chen","year":"2018","unstructured":"Chen H, Engkvist O, Wang Y et al (2018) The rise of deep learning in drug discovery. Drug Discovery Today 23:1241\u20131250. https:\/\/doi.org\/10.1016\/j.drudis.2018.01.039","journal-title":"Drug Discovery Today"},{"key":"10286_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2023.1250043","author":"Y Chen","year":"2023","unstructured":"Chen Y, Zhang M, Li W et al (2023) Drug repurposing based on the similarity gene expression signatures to explore for potential indications of quercetin: a case study of multiple sclerosis. Front Chem. https:\/\/doi.org\/10.3389\/fchem.2023.1250043","journal-title":"Front Chem"},{"key":"10286_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-024-04010-6","volume":"25","author":"Y-T Chen","year":"2025","unstructured":"Chen Y-T, Huang Y-C, Chen H-L et al (2025) Automatic segmentation of white matter lesions on multi-parametric MRI: convolutional neural network versus vision transformer. BMC Neurol 25:5. https:\/\/doi.org\/10.1186\/s12883-024-04010-6","journal-title":"BMC Neurol"},{"key":"10286_CR35","doi-asserted-by":"publisher","first-page":"4977","DOI":"10.1021\/jm4004285","volume":"57","author":"A Cherkasov","year":"2014","unstructured":"Cherkasov A, Muratov EN, Fourches D et al (2014) QSAR Modeling: Where Have You Been? Where Are You Going To? J Med Chem 57:4977\u20135010. https:\/\/doi.org\/10.1021\/jm4004285","journal-title":"J Med Chem"},{"key":"10286_CR36","unstructured":"Chithrananda S, Grand G, Ramsundar B (2020) ChemBERTa: Large-Scale Self-Supervised Pretraining for Molecular Property Prediction"},{"key":"10286_CR37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40259-020-00462-7","volume":"35","author":"K Chwojnicki","year":"2021","unstructured":"Chwojnicki K, Iwaszkiewicz-Grze\u015b D, Jankowska A et al (2021) Administration of CD4\u2009+\u2009CD25highCD127\u2212FoxP3\u2009+\u2009regulatory T cells for relapsing-remitting multiple sclerosis: a phase 1 study. BioDrugs 35:47\u201360. https:\/\/doi.org\/10.1007\/s40259-020-00462-7","journal-title":"BioDrugs"},{"key":"10286_CR38","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","volume":"18","author":"JA Cohen","year":"2019","unstructured":"Cohen JA, Comi G, Selmaj KW et al (2019) Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol 18:1021\u20131033. https:\/\/doi.org\/10.1016\/S1474-4422(19)30238-8","journal-title":"Lancet Neurol"},{"key":"10286_CR39","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL et al (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380:1829\u20131839. https:\/\/doi.org\/10.1016\/S0140-6736(12)61768-1","journal-title":"Lancet"},{"key":"10286_CR40","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/j.1476-5381.2011.01302.x","volume":"164","author":"CS Constantinescu","year":"2011","unstructured":"Constantinescu CS, Farooqi N, O\u2019Brien K, Gran B (2011) Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol 164:1079\u20131106. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01302.x","journal-title":"Br J Pharmacol"},{"key":"10286_CR41","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S1474-4422(21)00250-7","volume":"20","author":"J Correale","year":"2021","unstructured":"Correale J (2021) BTK inhibitors as potential therapies for multiple sclerosis. Lancet Neurol 20:689\u2013691. https:\/\/doi.org\/10.1016\/S1474-4422(21)00250-7","journal-title":"Lancet Neurol"},{"key":"10286_CR42","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/9781118298633.ch2","volume-title":"Multiple Sclerosis and CNS Inflammatory Disorders","author":"AH Cross","year":"2014","unstructured":"Cross AH, Piccio L (2014) Immunopathogenesis of Multiple Sclerosis. Multiple Sclerosis and CNS Inflammatory Disorders. Wiley, Ltd, pp 10\u201317"},{"key":"10286_CR43","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1177\/1352458511399114","volume":"17","author":"P Cunnea","year":"2011","unstructured":"Cunnea P, Mh\u00e1ille AN, McQuaid S et al (2011) Expression profiles of endoplasmic reticulum stress-related molecules in demyelinating lesions and multiple sclerosis. Mult Scler 17:808\u2013818. https:\/\/doi.org\/10.1177\/1352458511399114","journal-title":"Mult Scler"},{"key":"10286_CR44","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00415-019-09421-x","volume":"268","author":"N Cunniffe","year":"2021","unstructured":"Cunniffe N, Coles A (2021) Promoting remyelination in multiple sclerosis. J Neurol 268:30\u201344. https:\/\/doi.org\/10.1007\/s00415-019-09421-x","journal-title":"J Neurol"},{"key":"10286_CR45","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/pr.2011.57","volume":"71","author":"T Daikeler","year":"2012","unstructured":"Daikeler T, Tichelli A, Passweg J (2012) Complications of autologous hematopoietic stem cell transplantation for patients with autoimmune diseases. Pediatr Res 71:439\u2013444. https:\/\/doi.org\/10.1038\/pr.2011.57","journal-title":"Pediatr Res"},{"key":"10286_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci7070078","volume":"7","author":"N Dargahi","year":"2017","unstructured":"Dargahi N, Katsara M, Tselios T et al (2017) Multiple sclerosis: immunopathology and treatment update. Brain Sci 7:78. https:\/\/doi.org\/10.3390\/brainsci7070078","journal-title":"Brain Sci"},{"key":"10286_CR47","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri3871","volume":"15","author":"CA Dendrou","year":"2015","unstructured":"Dendrou CA, Fugger L, Friese MA (2015) Immunopathology of multiple sclerosis. Nat Rev Immunol 15:545\u2013558. https:\/\/doi.org\/10.1038\/nri3871","journal-title":"Nat Rev Immunol"},{"key":"10286_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/ph18070981","author":"D Dermawan","year":"2025","unstructured":"Dermawan D, Alotaiq N, Dermawan D, Alotaiq N (2025) From lab to clinic: how artificial intelligence (AI) is reshaping drug discovery timelines and industry outcomes. Pharmaceuticals. https:\/\/doi.org\/10.3390\/ph18070981","journal-title":"Pharmaceuticals"},{"key":"10286_CR49","doi-asserted-by":"publisher","first-page":"154880","DOI":"10.1016\/j.prp.2023.154880","volume":"251","author":"AS Doghish","year":"2023","unstructured":"Doghish AS, Elazazy O, Mohamed HH et al (2023) The role of miRNAs in multiple sclerosis pathogenesis, diagnosis, and therapeutic resistance. Pathol - Res Pract 251:154880. https:\/\/doi.org\/10.1016\/j.prp.2023.154880","journal-title":"Pathol - Res Pract"},{"key":"10286_CR50","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3390\/pharmaceutics15020516","volume":"15","author":"P Dragan","year":"2023","unstructured":"Dragan P, Merski M, Wi\u015bniewski S et al (2023) Chemokine Receptors\u2014Structure-Based Virtual Screening Assisted by Machine Learning. Pharmaceutics 15:516. https:\/\/doi.org\/10.3390\/pharmaceutics15020516","journal-title":"Pharmaceutics"},{"key":"10286_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.01107","author":"SS Duffy","year":"2019","unstructured":"Duffy SS, Keating BA, Moalem-Taylor G (2019) Adoptive transfer of regulatory T cells as a promising immunotherapy for the treatment of multiple sclerosis. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2019.01107","journal-title":"Front Neurosci"},{"key":"10286_CR52","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1185\/03007995.2011.583229","volume":"27","author":"J Dunn","year":"2011","unstructured":"Dunn J, Blight A (2011) Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Curr Med Res Opin 27:1415\u20131423. https:\/\/doi.org\/10.1185\/03007995.2011.583229","journal-title":"Curr Med Res Opin"},{"key":"10286_CR53","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1182\/blood-2010-08-303339","volume":"117","author":"M Dusseaux","year":"2011","unstructured":"Dusseaux M, Martin E, Serriari N et al (2011) Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17\u2013secreting T cells. Blood 117:1250\u20131259. https:\/\/doi.org\/10.1182\/blood-2010-08-303339","journal-title":"Blood"},{"key":"10286_CR54","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/ana.20736","volume":"59","author":"R Dutta","year":"2006","unstructured":"Dutta R, McDonough J, Yin X et al (2006) Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 59:478\u2013489. https:\/\/doi.org\/10.1002\/ana.20736","journal-title":"Ann Neurol"},{"key":"10286_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00784","author":"CM Dwyer","year":"2020","unstructured":"Dwyer CM, Nguyen L-T, Healy LM et al (2020) Multiple sclerosis as a syndrome\u2014implications for future management. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2020.00784","journal-title":"Front Neurol"},{"key":"10286_CR56","doi-asserted-by":"publisher","first-page":"5594","DOI":"10.4049\/jimmunol.1203331","volume":"191","author":"F Ebner","year":"2013","unstructured":"Ebner F, Brandt C, Thiele P et al (2013) Microglial Activation Milieu Controls Regulatory T Cell Responses. J Immunol 191:5594\u20135602. https:\/\/doi.org\/10.4049\/jimmunol.1203331","journal-title":"J Immunol"},{"key":"10286_CR57","doi-asserted-by":"publisher","first-page":"102003","DOI":"10.1016\/j.nicl.2019.102003","volume":"24","author":"F Eitel","year":"2019","unstructured":"Eitel F, Soehler E, Bellmann-Strobl J et al (2019) Uncovering convolutional neural network decisions for diagnosing multiple sclerosis on conventional MRI using layer-wise relevance propagation. Neuroimage Clin 24:102003\u2013102003. https:\/\/doi.org\/10.1016\/j.nicl.2019.102003","journal-title":"Neuroimage Clin"},{"key":"10286_CR58","doi-asserted-by":"crossref","unstructured":"Elkoroaristizabal A, Viv\u00f3 F, Calvi A et al (2024) Multiclass Lesion Detection Using Longitudinal MRI in Multiple Sclerosis","DOI":"10.3233\/FAIA240420"},{"key":"10286_CR59","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/eji.202149757","volume":"52","author":"B Engelhardt","year":"2022","unstructured":"Engelhardt B, Comabella M, Chan A (2022) Multiple sclerosis: immunopathological heterogeneity and its implications. Eur J Immunol 52:869\u2013881. https:\/\/doi.org\/10.1002\/eji.202149757","journal-title":"Eur J Immunol"},{"key":"10286_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22265-2","volume":"12","author":"A Eshaghi","year":"2021","unstructured":"Eshaghi A, Young AL, Wijeratne PA et al (2021) Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. Nat Commun 12:2078. https:\/\/doi.org\/10.1038\/s41467-021-22265-2","journal-title":"Nat Commun"},{"key":"10286_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13065-024-01374-1","volume":"19","author":"FB Farooq","year":"2025","unstructured":"Farooq FB, Idrees N, Noor E et al (2025) A computational approach to drug design for multiple sclerosis via QSPR modeling, chemical graph theory, and multi-criteria decision analysis. BMC Chem 19:1. https:\/\/doi.org\/10.1186\/s13065-024-01374-1","journal-title":"BMC Chem"},{"key":"10286_CR62","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1002\/jmri.25095","volume":"43","author":"MJ Fartaria","year":"2016","unstructured":"Fartaria MJ, Bonnier G, Roche A et al (2016) Automated detection of white matter and cortical lesions in early stages of multiple sclerosis. J Magn Reson Imaging 43:1445\u20131454. https:\/\/doi.org\/10.1002\/jmri.25095","journal-title":"J Magn Reson Imaging"},{"key":"10286_CR63","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/sj.bmt.1700944","volume":"20","author":"A Fassas","year":"1997","unstructured":"Fassas A, Anagnostopoulos A, Kazis A et al (1997) Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transpl 20:631\u2013638. https:\/\/doi.org\/10.1038\/sj.bmt.1700944","journal-title":"Bone Marrow Transpl"},{"key":"10286_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02431-1","volume":"21","author":"N Fattahi","year":"2021","unstructured":"Fattahi N, Saeedi Moghaddam S, Mohebi F et al (2021) Burden of multiple sclerosis in Iran from 1990 to 2017. BMC Neurol 21:400. https:\/\/doi.org\/10.1186\/s12883-021-02431-1","journal-title":"BMC Neurol"},{"key":"10286_CR65","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrneurol.2014.37","volume":"10","author":"MA Friese","year":"2014","unstructured":"Friese MA, Schattling B, Fugger L (2014) Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol 10:225\u2013238. https:\/\/doi.org\/10.1038\/nrneurol.2014.37","journal-title":"Nat Rev Neurol"},{"key":"10286_CR66","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/brain\/awp070","volume":"132","author":"JM Frischer","year":"2009","unstructured":"Frischer JM, Bramow S, Dal-Bianco A et al (2009) The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132:1175\u20131189. https:\/\/doi.org\/10.1093\/brain\/awp070","journal-title":"Brain"},{"key":"10286_CR67","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nature11007","volume":"485","author":"U F\u00fcnfschilling","year":"2012","unstructured":"F\u00fcnfschilling U, Supplie LM, Mahad D et al (2012) Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature 485:517\u2013521. https:\/\/doi.org\/10.1038\/nature11007","journal-title":"Nature"},{"key":"10286_CR68","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.drudis.2018.06.016","volume":"23","author":"F Ghasemi","year":"2018","unstructured":"Ghasemi F, Mehridehnavi A, P\u00e9rez-Garrido A, P\u00e9rez-S\u00e1nchez H (2018) Neural network and deep-learning algorithms used in QSAR studies: merits and drawbacks. Drug Discov Today 23:1784\u20131790. https:\/\/doi.org\/10.1016\/j.drudis.2018.06.016","journal-title":"Drug Discov Today"},{"key":"10286_CR69","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S et al (2010) A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. N Engl J Med 362:416\u2013426. https:\/\/doi.org\/10.1056\/NEJMoa0902533","journal-title":"N Engl J Med"},{"key":"10286_CR70","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/s41590-019-0444-8","volume":"20","author":"DI Godfrey","year":"2019","unstructured":"Godfrey DI, Koay H-F, McCluskey J, Gherardin NA (2019) The biology and functional importance of MAIT cells. Nat Immunol 20:1110\u20131128. https:\/\/doi.org\/10.1038\/s41590-019-0444-8","journal-title":"Nat Immunol"},{"key":"10286_CR71","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL et al (2012) Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. N Engl J Med 367:1098\u20131107. https:\/\/doi.org\/10.1056\/NEJMoa1114287","journal-title":"N Engl J Med"},{"key":"10286_CR72","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181a8260a","volume":"72","author":"T Goldschmidt","year":"2009","unstructured":"Goldschmidt T, Antel J, K\u00f6nig FB et al (2009) Remyelination capacity of the MS brain decreases with disease chronicity. Neurology 72:1914\u20131921. https:\/\/doi.org\/10.1212\/WNL.0b013e3181a8260a","journal-title":"Neurology"},{"key":"10286_CR73","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/ana.22240","volume":"68","author":"AD Goodman","year":"2010","unstructured":"Goodman AD, Brown TR, Edwards KR et al (2010) A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 68:494\u2013502. https:\/\/doi.org\/10.1002\/ana.22240","journal-title":"Ann Neurol"},{"key":"10286_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00781","author":"M Goyal","year":"2019","unstructured":"Goyal M, Khanna D, Rana PS et al (2019) Computational intelligence technique for prediction of multiple sclerosis based on serum cytokines. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2019.00781","journal-title":"Front Neurol"},{"key":"10286_CR75","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.25119","volume":"83","author":"AL Greenfield","year":"2018","unstructured":"Greenfield AL, Hauser SL (2018) B-cell therapy for multiple sclerosis: entering an era. Ann Neurol 83:13\u201326. https:\/\/doi.org\/10.1002\/ana.25119","journal-title":"Ann Neurol"},{"key":"10286_CR76","first-page":"408","volume":"86","author":"J Greenwood","year":"1995","unstructured":"Greenwood J, Wang Y, Calder VL (1995) Lymphocyte adhesion and transendothelial migration in the central nervous system: the role of LFA-1, ICAM-1, VLA-4 and VCAM-1. off. Immunology 86:408\u2013415","journal-title":"Immunology"},{"key":"10286_CR77","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ene.12798","volume":"22","author":"N Grigoriadis","year":"2015","unstructured":"Grigoriadis N, van Pesch V (2015) A basic overview of multiple sclerosis immunopathology. Eur J Neurol 22:3\u201313. https:\/\/doi.org\/10.1111\/ene.12798","journal-title":"Eur J Neurol"},{"key":"10286_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-025-05250-y","volume":"12","author":"F Guarnera","year":"2025","unstructured":"Guarnera F, Rondinella A, Crispino E et al (2025) MSLesSeg: baseline and benchmarking of a new Multiple Sclerosis Lesion Segmentation dataset. Sci Data 12:920. https:\/\/doi.org\/10.1038\/s41597-025-05250-y","journal-title":"Sci Data"},{"key":"10286_CR79","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1093\/brain\/awr128","volume":"134","author":"L Haider","year":"2011","unstructured":"Haider L, Fischer MT, Frischer JM et al (2011) Oxidative damage in multiple sclerosis lesions. Brain 134:1914\u20131924. https:\/\/doi.org\/10.1093\/brain\/awr128","journal-title":"Brain"},{"key":"10286_CR80","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0166-2236(96)10071-0","volume":"20","author":"GL Hall","year":"1997","unstructured":"Hall GL, Compston A, Scolding NJ (1997) Beta-interferon and multiple sclerosis. Trends Neurosci 20:63\u201367. https:\/\/doi.org\/10.1016\/S0166-2236(96)10071-0","journal-title":"Trends Neurosci"},{"key":"10286_CR81","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.neuron.2013.11.015","volume":"81","author":"TR Hammond","year":"2014","unstructured":"Hammond TR, Gadea A, Dupree J et al (2014) Astrocyte-derived Endothelin-1 inhibits remyelination through Notch activation. Neuron 81:588\u2013602. https:\/\/doi.org\/10.1016\/j.neuron.2013.11.015","journal-title":"Neuron"},{"key":"10286_CR82","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.clim.2008.05.002","volume":"128","author":"CT Harp","year":"2008","unstructured":"Harp CT, Lovett-Racke AE, Racke MK et al (2008) Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis. Clin Immunol 128:382\u2013391. https:\/\/doi.org\/10.1016\/j.clim.2008.05.002","journal-title":"Clin Immunol"},{"key":"10286_CR83","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-014-0485-1","volume":"14","author":"MD Hartley","year":"2014","unstructured":"Hartley MD, Altowaijri G, Bourdette D (2014) Remyelination and Multiple Sclerosis: therapeutic approaches and challenges. Curr Neurol Neurosci Rep 14:485. https:\/\/doi.org\/10.1007\/s11910-014-0485-1","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10286_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2021.104337","volume":"132","author":"M Hartmann","year":"2021","unstructured":"Hartmann M, Fenton N, Dobson R (2021) Current review and next steps for artificial intelligence in multiple sclerosis risk research. Comput Biol Med 132:104337. https:\/\/doi.org\/10.1016\/j.compbiomed.2021.104337","journal-title":"Comput Biol Med"},{"key":"10286_CR85","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","volume":"360","author":"H-P Hartung","year":"2002","unstructured":"Hartung H-P, Gonsette R, Konig N et al (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360:2018\u20132025. https:\/\/doi.org\/10.1016\/S0140-6736(02)12023-X","journal-title":"Lancet"},{"key":"10286_CR86","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G et al (2017) Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 376:221\u2013234. https:\/\/doi.org\/10.1056\/NEJMoa1601277","journal-title":"N Engl J Med"},{"key":"10286_CR87","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/pharmaceutics16010003","volume":"16","author":"M Hecker","year":"2024","unstructured":"Hecker M, Frahm N, Zettl UK (2024) Update and Application of a Deep Learning Model for the Prediction of Interactions between Drugs Used by Patients with Multiple Sclerosis. Pharmaceutics 16:3. https:\/\/doi.org\/10.3390\/pharmaceutics16010003","journal-title":"Pharmaceutics"},{"key":"10286_CR88","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/ana.21800","volume":"66","author":"APD Henderson","year":"2009","unstructured":"Henderson APD, Barnett MH, Parratt JDE, Prineas JW (2009) Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann Neurol 66:739\u2013753. https:\/\/doi.org\/10.1002\/ana.21800","journal-title":"Ann Neurol"},{"key":"10286_CR89","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1172\/JCI91301","volume":"127","author":"S Horng","year":"2017","unstructured":"Horng S, Therattil A, Moyon S et al (2017) Astrocytic tight junctions control inflammatory CNS lesion pathogenesis. J Clin Invest 127:3136\u20133151. https:\/\/doi.org\/10.1172\/JCI91301","journal-title":"J Clin Invest"},{"key":"10286_CR90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003907","volume":"9","author":"J Hornig","year":"2013","unstructured":"Hornig J, Fr\u00f6b F, Vogl MR et al (2013) The transcription factors Sox10 and Myrf define an essential regulatory network module in differentiating oligodendrocytes. PLoS Genet 9:e1003907. https:\/\/doi.org\/10.1371\/journal.pgen.1003907","journal-title":"PLoS Genet"},{"key":"10286_CR91","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1093\/brain\/awr182","volume":"134","author":"OW Howell","year":"2011","unstructured":"Howell OW, Reeves CA, Nicholas R et al (2011) Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 134:2755\u20132771. https:\/\/doi.org\/10.1093\/brain\/awr182","journal-title":"Brain"},{"key":"10286_CR92","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2025-102876","volume":"15","author":"L Huang","year":"2025","unstructured":"Huang L, Shi J, Li H, Lin Q (2025) Mendelian randomisation and single-cell transcriptomic analyses reveal serotonin promotes multiple sclerosis progression by suppressing adenosine deaminase activity. BMJ Open 15:e102876. https:\/\/doi.org\/10.1136\/bmjopen-2025-102876","journal-title":"BMJ Open"},{"key":"10286_CR93","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav7188","volume":"365","author":"International Multiple Sclerosis Genetics Consortium","year":"2019","unstructured":"International Multiple Sclerosis Genetics Consortium (2019) Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 365:eaav7188. https:\/\/doi.org\/10.1126\/science.aav7188","journal-title":"Science"},{"key":"10286_CR94","doi-asserted-by":"crossref","unstructured":"Isensee F, Petersen J, Klein A et al (2018) nnU-Net. Self-adapting Framework for U-Net-Based Medical Image Segmentation","DOI":"10.1007\/978-3-658-25326-4_7"},{"key":"10286_CR95","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/ana.410390304","volume":"39","author":"LD Jacobs","year":"1996","unstructured":"Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285\u2013294. https:\/\/doi.org\/10.1002\/ana.410390304","journal-title":"Ann Neurol"},{"key":"10286_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-44675-6","volume":"13","author":"A Jagielska","year":"2023","unstructured":"Jagielska A, Radzwill K, Espinosa-Hoyos D et al (2023) Artificial axons as a biomimetic 3D myelination platform for the discovery and validation of promyelinating compounds. Sci Rep 13:19529. https:\/\/doi.org\/10.1038\/s41598-023-44675-6","journal-title":"Sci Rep"},{"key":"10286_CR97","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12974-017-0929-z","volume":"14","author":"S Jarius","year":"2017","unstructured":"Jarius S, K\u00f6nig FB, Metz I et al (2017) Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis. J Neuroinflammation 14:171. https:\/\/doi.org\/10.1186\/s12974-017-0929-z","journal-title":"J Neuroinflammation"},{"key":"10286_CR98","doi-asserted-by":"publisher","first-page":"9186","DOI":"10.1523\/JNEUROSCI.1444-16.2016","volume":"36","author":"MA Jeffries","year":"2016","unstructured":"Jeffries MA, Urbanek K, Torres L et al (2016) ERK1\/2 activation in preexisting oligodendrocytes of adult mice drives new myelin synthesis and enhanced CNS function. J Neurosci 36:9186\u20139200. https:\/\/doi.org\/10.1523\/JNEUROSCI.1444-16.2016","journal-title":"J Neurosci"},{"key":"10286_CR99","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/ni.2513","volume":"14","author":"Q Ji","year":"2013","unstructured":"Ji Q, Castelli L, Goverman JM (2013) MHC class I\u2013restricted myelin epitopes are cross-presented by Tip-DCs that promote determinant spreading to CD8\u2009+\u2009T cells. Nat Immunol 14:254\u2013261. https:\/\/doi.org\/10.1038\/ni.2513","journal-title":"Nat Immunol"},{"key":"10286_CR100","doi-asserted-by":"crossref","unstructured":"Joscelyn J, Ochoa-Rep\u00e1raz J, Kasper L (2020) Principles of Immunotherapy. In: Rizvi SA, Cahill JF, Coyle PK (eds) Clinical Neuroimmunology: Multiple Sclerosis and Related Disorders. Springer International Publishing, Cham, pp 17\u201342","DOI":"10.1007\/978-3-030-24436-1_2"},{"key":"10286_CR101","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/S2213-2600(21)00358-1","volume":"9","author":"AC Kalil","year":"2021","unstructured":"Kalil AC, Stebbing J (2021) Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial. Lancet Respir Med 9:1349\u20131351. https:\/\/doi.org\/10.1016\/S2213-2600(21)00358-1","journal-title":"Lancet Respir Med"},{"key":"10286_CR102","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/386724a0","volume":"386","author":"MR Kaplan","year":"1997","unstructured":"Kaplan MR, Meyer-Franke A, Lambert S et al (1997) Induction of sodium channel clustering by oligodendrocytes. Nature 386:724\u2013728. https:\/\/doi.org\/10.1038\/386724a0","journal-title":"Nature"},{"key":"10286_CR103","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue E-W, O\u2019Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387\u2013401. https:\/\/doi.org\/10.1056\/NEJMoa0909494","journal-title":"N Engl J Med"},{"key":"10286_CR104","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1056\/NEJMoa1501481","volume":"373","author":"L Kappos","year":"2015","unstructured":"Kappos L, Wiendl H, Selmaj K et al (2015) Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 373:1418\u20131428. https:\/\/doi.org\/10.1056\/NEJMoa1501481","journal-title":"N Engl J Med"},{"key":"10286_CR105","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC et al (2018) Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 391:1263\u20131273. https:\/\/doi.org\/10.1016\/S0140-6736(18)30475-6","journal-title":"Lancet"},{"key":"10286_CR106","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","volume":"78","author":"L Kappos","year":"2021","unstructured":"Kappos L, Fox RJ, Burcklen M et al (2021) Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurol 78:558\u2013567. https:\/\/doi.org\/10.1001\/jamaneurol.2021.0405","journal-title":"JAMA Neurol"},{"key":"10286_CR107","doi-asserted-by":"publisher","DOI":"10.1007\/s44197-025-00353-6","volume":"15","author":"G Khan","year":"2025","unstructured":"Khan G, Hashim MJ (2025) Epidemiology of multiple sclerosis: global, regional, national and sub-national-level estimates and future projections. J Epidemiol Glob Health 15:21. https:\/\/doi.org\/10.1007\/s44197-025-00353-6","journal-title":"J Epidemiol Glob Health"},{"key":"10286_CR108","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2165\/11591110-000000000-00000","volume":"25","author":"BC Kieseier","year":"2011","unstructured":"Kieseier BC (2011) The mechanism of action of interferon-\u03b2 in relapsing multiple sclerosis. CNS Drugs 25:491\u2013502. https:\/\/doi.org\/10.2165\/11591110-000000000-00000","journal-title":"CNS Drugs"},{"key":"10286_CR109","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao5563","volume":"11","author":"L Klotz","year":"2019","unstructured":"Klotz L, Eschborn M, Lindner M et al (2019) Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects. Sci Transl Med 11:eaao5563. https:\/\/doi.org\/10.1126\/scitranslmed.aao5563","journal-title":"Sci Transl Med"},{"key":"10286_CR110","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1126\/science.aan4665","volume":"360","author":"MD Kornberg","year":"2018","unstructured":"Kornberg MD, Bhargava P, Kim PM et al (2018) Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science 360:449\u2013453. https:\/\/doi.org\/10.1126\/science.aan4665","journal-title":"Science"},{"key":"10286_CR111","doi-asserted-by":"publisher","first-page":"7670","DOI":"10.1038\/s41467-022-35357-4","volume":"13","author":"P Kosa","year":"2022","unstructured":"Kosa P, Barbour C, Varosanec M et al (2022) Molecular models of multiple sclerosis severity identify heterogeneity of pathogenic mechanisms. Nat Commun 13:7670. https:\/\/doi.org\/10.1038\/s41467-022-35357-4","journal-title":"Nat Commun"},{"key":"10286_CR112","doi-asserted-by":"publisher","first-page":"111366","DOI":"10.1016\/j.mad.2020.111366","volume":"192","author":"PN Koutsoudaki","year":"2020","unstructured":"Koutsoudaki PN, Papadopoulos D, Passias P-G et al (2020) Cellular senescence and failure of myelin repair in multiple sclerosis. Mech Ageing Dev 192:111366. https:\/\/doi.org\/10.1016\/j.mad.2020.111366","journal-title":"Mech Ageing Dev"},{"key":"10286_CR113","doi-asserted-by":"publisher","first-page":"107231","DOI":"10.1016\/j.compbiomed.2023.107231","volume":"163","author":"A Krishna Swaroop","year":"2023","unstructured":"Krishna Swaroop A, Krishnan Namboori PK, Esakkimuthukumar M et al (2023) Leveraging decagonal in-silico strategies for uncovering IL-6 inhibitors with precision. Comput Biol Med 163:107231. https:\/\/doi.org\/10.1016\/j.compbiomed.2023.107231","journal-title":"Comput Biol Med"},{"key":"10286_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2020.102445","volume":"28","author":"J Kr\u00fcger","year":"2020","unstructured":"Kr\u00fcger J, Opfer R, Gessert N et al (2020) Fully automated longitudinal segmentation of new or enlarged multiple sclerosis lesions using 3D convolutional neural networks. Neuroimage Clin 28:102445. https:\/\/doi.org\/10.1016\/j.nicl.2020.102445","journal-title":"Neuroimage Clin"},{"key":"10286_CR115","doi-asserted-by":"publisher","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","volume":"92","author":"J Kuhle","year":"2019","unstructured":"Kuhle J, Kropshofer H, Haering DA et al (2019) Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 92:e1007\u2013e1015. https:\/\/doi.org\/10.1212\/WNL.0000000000007032","journal-title":"Neurology"},{"key":"10286_CR116","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jaut.2016.04.003","volume":"72","author":"A Laroni","year":"2016","unstructured":"Laroni A, Armentani E, Kerlero de Rosbo N et al (2016) Dysregulation of regulatory CD56bright NK cells\/T cells interactions in multiple sclerosis. J Autoimmun 72:8\u201318. https:\/\/doi.org\/10.1016\/j.jaut.2016.04.003","journal-title":"J Autoimmun"},{"key":"10286_CR117","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature11314","volume":"487","author":"Y Lee","year":"2012","unstructured":"Lee Y, Morrison BM, Li Y et al (2012) Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 487:443\u2013448. https:\/\/doi.org\/10.1038\/nature11314","journal-title":"Nature"},{"key":"10286_CR118","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","volume":"34","author":"TP Leist","year":"2011","unstructured":"Leist TP, Weissert R (2011) Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol 34:28. https:\/\/doi.org\/10.1097\/WNF.0b013e318204cd90","journal-title":"Clin Neuropharmacol"},{"key":"10286_CR119","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","volume":"13","author":"TP Leist","year":"2014","unstructured":"Leist TP, Comi G, Cree BAC et al (2014) Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol 13:257\u2013267. https:\/\/doi.org\/10.1016\/S1474-4422(14)70005-5","journal-title":"Lancet Neurol"},{"key":"10286_CR120","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12021-017-9348-7","volume":"16","author":"\u017d Lesjak","year":"2018","unstructured":"Lesjak \u017d, Galimzianova A, Koren A et al (2018) A Novel Public MR Image Dataset of Multiple Sclerosis Patients With Lesion Segmentations Based on Multi-rater Consensus. Neuroinformatics 16:51\u201363. https:\/\/doi.org\/10.1007\/s12021-017-9348-7","journal-title":"Neuroinformatics"},{"key":"10286_CR121","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow SA, Guttenplan KA, Clarke LE et al (2017) Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541:481\u2013487. https:\/\/doi.org\/10.1038\/nature21029","journal-title":"Nature"},{"key":"10286_CR122","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jneuroim.2006.07.006","volume":"180","author":"H Link","year":"2006","unstructured":"Link H, Huang Y-M (2006) Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol 180:17\u201328. https:\/\/doi.org\/10.1016\/j.jneuroim.2006.07.006","journal-title":"J Neuroimmunol"},{"key":"10286_CR123","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41582-019-0184-2","volume":"15","author":"AF Lloyd","year":"2019","unstructured":"Lloyd AF, Miron VE (2019) The pro-remyelination properties of microglia in the central nervous system. Nat Rev Neurol 15:447\u2013458. https:\/\/doi.org\/10.1038\/s41582-019-0184-2","journal-title":"Nat Rev Neurol"},{"key":"10286_CR124","doi-asserted-by":"publisher","first-page":"e113936","DOI":"10.1371\/journal.pone.0113936","volume":"9","author":"S Llufriu","year":"2014","unstructured":"Llufriu S, Sep\u00falveda M, Blanco Y et al (2014) Randomized Placebo-Controlled Phase II Trial of Autologous Mesenchymal Stem Cells in Multiple Sclerosis. PLoS ONE 9:e113936. https:\/\/doi.org\/10.1371\/journal.pone.0113936","journal-title":"PLoS ONE"},{"key":"10286_CR125","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1076421","author":"L Lorefice","year":"2023","unstructured":"Lorefice L, Pitzalis M, Murgia F et al (2023) Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis. Front Genet. https:\/\/doi.org\/10.3389\/fgene.2023.1076421","journal-title":"Front Genet"},{"key":"10286_CR126","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01265","author":"N Lotfi","year":"2019","unstructured":"Lotfi N, Thome R, Rezaei N et al (2019) Roles of GM-CSF in the pathogenesis of autoimmune diseases: an update. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2019.01265","journal-title":"Front Immunol"},{"key":"10286_CR127","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/s41598-020-58131-2","volume":"10","author":"N Lotfi","year":"2020","unstructured":"Lotfi N, Zhang G-X, Esmaeil N, Rostami A (2020) Evaluation of the effect of GM-CSF blocking on the phenotype and function of human monocytes. Sci Rep 10:1567. https:\/\/doi.org\/10.1038\/s41598-020-58131-2","journal-title":"Sci Rep"},{"key":"10286_CR128","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000516559","volume":"29","author":"F Lotfi","year":"2021","unstructured":"Lotfi F, Mansourian M, Mirmoayyeb O et al (2021) Association of exposure to particulate matters and multiple sclerosis: a systematic review and meta-analysis. Neuroimmunomodulation 29:21\u201327. https:\/\/doi.org\/10.1159\/000516559","journal-title":"Neuroimmunomodulation"},{"key":"10286_CR129","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrn1847","volume":"7","author":"A Louvi","year":"2006","unstructured":"Louvi A, Artavanis-Tsakonas S (2006) Notch signalling in vertebrate neural development. Nat Rev Neurosci 7:93\u2013102. https:\/\/doi.org\/10.1038\/nrn1847","journal-title":"Nat Rev Neurosci"},{"key":"10286_CR130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ncl.2004.09.003","volume":"23","author":"FD Lublin","year":"2005","unstructured":"Lublin FD (2005) Clinical features and diagnosis of multiple sclerosis. Neurol Clin 23:1\u201315. https:\/\/doi.org\/10.1016\/j.ncl.2004.09.003","journal-title":"Neurol Clin"},{"key":"10286_CR131","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA et al (2014) Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 83:278\u2013286. https:\/\/doi.org\/10.1212\/WNL.0000000000000560","journal-title":"Neurology"},{"key":"10286_CR132","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/1531-8249(200006)47","volume":"47","author":"C Lucchinetti","year":"2000","unstructured":"Lucchinetti C, Br\u00fcck W, Parisi J et al (2000) Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 47:707\u2013717. https:\/\/doi.org\/10.1002\/1531-8249(200006)47:6%253C707::AID-ANA3%253E3.0.CO;2-Q","journal-title":"Ann Neurol"},{"key":"10286_CR133","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1016\/j.celrep.2017.10.094","volume":"21","author":"SE Lutz","year":"2017","unstructured":"Lutz SE, Smith JR, Kim DH et al (2017) Caveolin1 Is Required for Th1 Cell Infiltration, but Not Tight Junction Remodeling, at the Blood-Brain Barrier in Autoimmune Neuroinflammation. Cell Rep 21:2104\u20132117. https:\/\/doi.org\/10.1016\/j.celrep.2017.10.094","journal-title":"Cell Rep"},{"issue":"1","key":"10286_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-09773-y","volume":"10","author":"L Madireddy","year":"2019","unstructured":"Madireddy L, Patsopoulos NA, Cotsapas C et al (2019) A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis. Nat Commun 10(1):1\u201312. https:\/\/doi.org\/10.1038\/s41467-019-09773-y","journal-title":"Nat Commun"},{"key":"10286_CR135","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1007\/s11030-021-10359-4","volume":"26","author":"TT Mai","year":"2022","unstructured":"Mai TT, Nguyen PG, Le M-T et al (2022) Discovery of small molecular inhibitors for interleukin-33\/ST2 protein\u2013protein interaction: a virtual screening, molecular dynamics simulations and binding free energy calculations. Mol Divers 26:2659\u20132678. https:\/\/doi.org\/10.1007\/s11030-021-10359-4","journal-title":"Mol Divers"},{"key":"10286_CR136","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s12031-025-02446-0","volume":"75","author":"TA Majrashi","year":"2025","unstructured":"Majrashi TA, Alsayari A, Alshahrani MY et al (2025) Irilone and Lupinisoflavone C as Potential Plant-Based Modulators of S1PR1 for Neuroimmune Modulation in Multiple Sclerosis: Insights from Molecular Docking and Dynamics. J Mol Neurosci 75:156. https:\/\/doi.org\/10.1007\/s12031-025-02446-0","journal-title":"J Mol Neurosci"},{"key":"10286_CR137","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/s41423-020-00618-z","volume":"18","author":"MJ Mansilla","year":"2021","unstructured":"Mansilla MJ, Presas-Rodr\u00edguez S, Teniente-Serra A et al (2021) Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy. Cell Mol Immunol 18:1353\u20131374. https:\/\/doi.org\/10.1038\/s41423-020-00618-z","journal-title":"Cell Mol Immunol"},{"key":"10286_CR138","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.805657","author":"JA Mapunda","year":"2022","unstructured":"Mapunda JA, Tibar H, Regragui W, Engelhardt B (2022) How does the immune system enter the brain? Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.805657","journal-title":"Front Immunol"},{"key":"10286_CR139","doi-asserted-by":"publisher","DOI":"10.1530\/VB-19-0033","author":"L Marchetti","year":"2020","unstructured":"Marchetti L, Engelhardt B (2020) Immune cell trafficking across the blood-brain barrier in the absence and presence of neuroinflammation. Vascular Biology. https:\/\/doi.org\/10.1530\/VB-19-0033","journal-title":"Vascular Biology"},{"key":"10286_CR140","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3233\/BPL-200100","volume":"5","author":"E Martin","year":"2019","unstructured":"Martin E, Aigrot M-S, Grenningloh R et al (2019) Bruton\u2019s Tyrosine Kinase Inhibition Promotes Myelin Repair. Brain Plast 5:123\u2013133. https:\/\/doi.org\/10.3233\/BPL-200100","journal-title":"Brain Plast"},{"key":"10286_CR141","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10072-009-0142-7","volume":"30","author":"V Martinelli","year":"2009","unstructured":"Martinelli V, Radaelli M, Straffi L et al (2009) Mitoxantrone: benefits and risks in multiple sclerosis patients. Neurol Sci 30:167\u2013170. https:\/\/doi.org\/10.1007\/s10072-009-0142-7","journal-title":"Neurol Sci"},{"key":"10286_CR142","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nrneurol.2010.35","volume":"6","author":"G Martino","year":"2010","unstructured":"Martino G, Franklin RJM, Van Evercooren AB, Kerr DA (2010) Stem cell transplantation in multiple sclerosis: current status and future prospects. Nat Rev Neurol 6:247\u2013255. https:\/\/doi.org\/10.1038\/nrneurol.2010.35","journal-title":"Nat Rev Neurol"},{"key":"10286_CR143","doi-asserted-by":"publisher","first-page":"2727042","DOI":"10.1155\/2020\/2727042","volume":"2020","author":"E Martynova","year":"2020","unstructured":"Martynova E, Goyal M, Johri S et al (2020) Serum and Cerebrospinal Fluid Cytokine Biomarkers for Diagnosis of Multiple Sclerosis. Mediat Inflamm 2020:2727042. https:\/\/doi.org\/10.1155\/2020\/2727042","journal-title":"Mediat Inflamm"},{"key":"10286_CR144","unstructured":"Marzieh Soltani S, Sardari H, Sabzyan F (2023) Ghasemi Towards Screening and Repurposing of Approved Drugs for the Treatment of COVID-19 Using Molecular Docking. PhysicalChemistryResearch"},{"key":"10286_CR145","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1007\/s10278-024-01031-y","volume":"37","author":"JD Mayfield","year":"2024","unstructured":"Mayfield JD, Murtagh R, Ciotti J et al (2024) Time-Dependent Deep Learning Prediction of Multiple Sclerosis Disability. J Digit Imaging Inf med 37:3231\u20133249. https:\/\/doi.org\/10.1007\/s10278-024-01031-y","journal-title":"J Digit Imaging Inf med"},{"key":"10286_CR146","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nm1202","volume":"11","author":"EJ McMahon","year":"2005","unstructured":"McMahon EJ, Bailey SL, Castenada CV et al (2005) Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 11:335\u2013339. https:\/\/doi.org\/10.1038\/nm1202","journal-title":"Nat Med"},{"key":"10286_CR147","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1096\/fj.09-136200","volume":"23","author":"N Melzer","year":"2009","unstructured":"Melzer N, Meuth SG, Wiendl H (2009) CD8\u2009+\u2009T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability. FASEB J 23:3659\u20133673. https:\/\/doi.org\/10.1096\/fj.09-136200","journal-title":"FASEB J"},{"key":"10286_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.ailsci.2022.100042","volume":"2","author":"L Menestrina","year":"2022","unstructured":"Menestrina L, Recanatini M (2022) An unsupervised computational pipeline identifies potential repurposable drugs to treat Huntington\u2019s disease and multiple sclerosis. Artif Intell Life Sci 2:100042. https:\/\/doi.org\/10.1016\/j.ailsci.2022.100042","journal-title":"Artif Intell Life Sci"},{"key":"10286_CR149","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/brain\/awz017","volume":"142","author":"I Mexhitaj","year":"2019","unstructured":"Mexhitaj I, Nyirenda MH, Li R et al (2019) Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis. Brain 142:617\u2013632. https:\/\/doi.org\/10.1093\/brain\/awz017","journal-title":"Brain"},{"key":"10286_CR150","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1007\/s12035-019-01856-7","volume":"57","author":"L Mezzaroba","year":"2020","unstructured":"Mezzaroba L, Sim\u00e3o ANC, Oliveira SR et al (2020) Antioxidant and Anti-inflammatory Diagnostic Biomarkers in Multiple Sclerosis: A Machine Learning Study. Mol Neurobiol 57:2167\u20132178. https:\/\/doi.org\/10.1007\/s12035-019-01856-7","journal-title":"Mol Neurobiol"},{"key":"10286_CR151","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11090446","volume":"11","author":"DP Mihai","year":"2019","unstructured":"Mihai DP, Nitulescu GM, Ion GND et al (2019) Computational drug repurposing algorithm targeting TRPA1 calcium channel as a potential therapeutic solution for multiple sclerosis. Pharmaceutics 11:446. https:\/\/doi.org\/10.3390\/pharmaceutics11090446","journal-title":"Pharmaceutics"},{"key":"10286_CR152","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1474-4422(08)70200-X","volume":"7","author":"DD Mikol","year":"2008","unstructured":"Mikol DD, Barkhof F, Chang P et al (2008) Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7:903\u2013914. https:\/\/doi.org\/10.1016\/S1474-4422(08)70200-X","journal-title":"Lancet Neurol"},{"key":"10286_CR153","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00005","author":"EA Mills","year":"2018","unstructured":"Mills EA, Ogrodnik MA, Plave A, Mao-Draayer Y (2018) Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2018.00005","journal-title":"Front Neurol"},{"key":"10286_CR154","doi-asserted-by":"publisher","first-page":"A387","DOI":"10.1016\/j.autrev.2009.11.010","volume":"9","author":"R Milo","year":"2010","unstructured":"Milo R, Kahana E (2010) Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 9:A387\u2013A394. https:\/\/doi.org\/10.1016\/j.autrev.2009.11.010","journal-title":"Autoimmun Rev"},{"key":"10286_CR155","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/brain\/awu045","volume":"137","author":"C Minten","year":"2014","unstructured":"Minten C, Alt C, Gentner M et al (2014) DARC shuttles inflammatory chemokines across the blood\u2013brain barrier during autoimmune central nervous system inflammation. Brain 137:1454\u20131469. https:\/\/doi.org\/10.1093\/brain\/awu045","journal-title":"Brain"},{"key":"10286_CR156","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/nn.3469","volume":"16","author":"VE Miron","year":"2013","unstructured":"Miron VE, Boyd A, Zhao J-W et al (2013) M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci 16:1211\u20131218. https:\/\/doi.org\/10.1038\/nn.3469","journal-title":"Nat Neurosci"},{"key":"10286_CR157","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12071496","author":"AE Mohr","year":"2024","unstructured":"Mohr AE, Ortega-Santos CP, Whisner CM et al (2024) Navigating challenges and opportunities in multi-omics integration for personalized healthcare. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines12071496","journal-title":"Biomedicines"},{"key":"10286_CR158","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L et al (2017) Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 376:209\u2013220. https:\/\/doi.org\/10.1056\/NEJMoa1606468","journal-title":"N Engl J Med"},{"key":"10286_CR159","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","volume":"380","author":"X Montalban","year":"2019","unstructured":"Montalban X, Arnold DL, Weber MS et al (2019) Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. N Engl J Med 380:2406\u20132417. https:\/\/doi.org\/10.1056\/NEJMoa1901981","journal-title":"N Engl J Med"},{"key":"10286_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102647","volume":"19","author":"T Moser","year":"2020","unstructured":"Moser T, Akg\u00fcn K, Proschmann U et al (2020) The role of TH17 cells in multiple sclerosis: therapeutic implications. Autoimmun Rev 19:102647. https:\/\/doi.org\/10.1016\/j.autrev.2020.102647","journal-title":"Autoimmun Rev"},{"key":"10286_CR161","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbi.2010.01.014","volume":"24","author":"\u00c1C Murphy","year":"2010","unstructured":"Murphy \u00c1C, Lalor SJ, Lynch MA, Mills KHG (2010) Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun 24:641\u2013651. https:\/\/doi.org\/10.1016\/j.bbi.2010.01.014","journal-title":"Brain Behav Immun"},{"key":"10286_CR162","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/annurev-physiol-022516-034339","volume":"79","author":"PJ Murray","year":"2017","unstructured":"Murray PJ (2017) Macrophage polarization. Annu Rev Physiol 79:541\u2013566. https:\/\/doi.org\/10.1146\/annurev-physiol-022516-034339","journal-title":"Annu Rev Physiol"},{"key":"10286_CR163","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","volume":"41","author":"PJ Murray","year":"2014","unstructured":"Murray PJ, Allen JE, Biswas SK et al (2014) Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines. Immunity 41:14\u201320. https:\/\/doi.org\/10.1016\/j.immuni.2014.06.008","journal-title":"Immunity"},{"key":"10286_CR164","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1177\/1352458519881761","volume":"26","author":"RT Naismith","year":"2020","unstructured":"Naismith RT, Wolinsky JS, Wundes A et al (2020a) Diroximel fumarate (DRF) in patients with relapsing\u2013remitting multiple sclerosis: interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Mult Scler 26:1729\u20131739. https:\/\/doi.org\/10.1177\/1352458519881761","journal-title":"Mult Scler"},{"key":"10286_CR165","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40263-020-00700-0","volume":"34","author":"RT Naismith","year":"2020","unstructured":"Naismith RT, Wundes A, Ziemssen T et al (2020b) Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing\u2013remitting multiple sclerosis: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. CNS Drugs 34:185\u2013196. https:\/\/doi.org\/10.1007\/s40263-020-00700-0","journal-title":"CNS Drugs"},{"key":"10286_CR166","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1212\/WNL.0000000000003660","volume":"88","author":"RA Nash","year":"2017","unstructured":"Nash RA, Hutton GJ, Racke MK et al (2017) High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology 88:842\u2013852. https:\/\/doi.org\/10.1212\/WNL.0000000000003660","journal-title":"Neurology"},{"key":"10286_CR167","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s10753-018-0872-x","volume":"42","author":"F Navabi","year":"2019","unstructured":"Navabi F, Shaygannejad V, Abbasirad F et al (2019) Immunoregulatory effects of silymarin on proliferation and activation of Th1 cells isolated from newly diagnosed and IFN-\u00df1b-treated MS patients. Inflammation 42:54\u201363. https:\/\/doi.org\/10.1007\/s10753-018-0872-x","journal-title":"Inflammation"},{"key":"10286_CR168","doi-asserted-by":"publisher","DOI":"10.1142\/S0219720021500062","volume":"19","author":"F Nazem","year":"2021","unstructured":"Nazem F, Ghasemi F, Fassihi A, Dehnavi AM (2021) 3D u-net: a voxel-based method in binding site prediction of protein structure. J Bioinform Comput Biol 19:2150006. https:\/\/doi.org\/10.1142\/S0219720021500062","journal-title":"J Bioinform Comput Biol"},{"key":"10286_CR169","doi-asserted-by":"publisher","DOI":"10.4103\/jmss.jmss_142_21","volume":"13","author":"F Nazem","year":"2023","unstructured":"Nazem F, Ghasemi F, Fassihi A et al (2023) A GU-net-based architecture predicting ligand\u2013protein-binding atoms. Journal of Medical Signals & Sensors 13:1. https:\/\/doi.org\/10.4103\/jmss.jmss_142_21","journal-title":"Journal of Medical Signals & Sensors"},{"key":"10286_CR170","doi-asserted-by":"publisher","first-page":"102368","DOI":"10.1016\/j.jocs.2024.102368","volume":"81","author":"F Nazem","year":"2024","unstructured":"Nazem F, Rasti R, Fassihi A et al (2024) Deep attention network for identifying ligand-protein binding sites. J Comput Sci 81:102368\u2013102368. https:\/\/doi.org\/10.1016\/j.jocs.2024.102368","journal-title":"J Comput Sci"},{"key":"10286_CR171","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.zemedi.2018.10.004","volume":"29","author":"H Neeb","year":"2019","unstructured":"Neeb H, Schenk J (2019) Multivariate prediction of multiple sclerosis using robust quantitative MR-based image metrics. Z Med Phys 29:262\u2013271. https:\/\/doi.org\/10.1016\/j.zemedi.2018.10.004","journal-title":"Z Med Phys"},{"key":"10286_CR172","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.msard.2015.06.004","volume":"4","author":"SD Newsome","year":"2015","unstructured":"Newsome SD, Guo S, Altincatal A et al (2015) Impact of peginterferon beta-1a and disease factors on quality of life in multiple sclerosis. Mult Scler Relat Disord 4:350\u2013357. https:\/\/doi.org\/10.1016\/j.msard.2015.06.004","journal-title":"Mult Scler Relat Disord"},{"key":"10286_CR173","doi-asserted-by":"publisher","DOI":"10.3390\/ph18091271","author":"SK Niazi","year":"2025","unstructured":"Niazi SK (2025) Artificial intelligence in small-molecule drug discovery: a critical review of methods, applications, and real-world outcomes. Pharmaceuticals. https:\/\/doi.org\/10.3390\/ph18091271","journal-title":"Pharmaceuticals"},{"key":"10286_CR174","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nm.2324","volume":"17","author":"I Niki\u0107","year":"2011","unstructured":"Niki\u0107 I, Merkler D, Sorbara C et al (2011) A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med 17:495\u2013499. https:\/\/doi.org\/10.1038\/nm.2324","journal-title":"Nat Med"},{"key":"10286_CR175","doi-asserted-by":"crossref","unstructured":"Nishihara H, Engelhardt B (2022) Brain Barriers and Multiple Sclerosis: Novel Treatment Approaches from a Brain Barriers Perspective. In: Cader Z, Neuhaus W (eds) Physiology, Pharmacology and Pathology of the Blood-Brain Barrier. Springer International Publishing, Cham, pp 295\u2013329","DOI":"10.1007\/164_2020_407"},{"key":"10286_CR176","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","volume":"89","author":"L Novakova","year":"2017","unstructured":"Novakova L, Zetterberg H, Sundstr\u00f6m P et al (2017) Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology 89:2230\u20132237. https:\/\/doi.org\/10.1212\/WNL.0000000000004683","journal-title":"Neurology"},{"key":"10286_CR177","unstructured":"Number of people with MS | Atlas of MS https:\/\/atlasofms.org\/map\/global\/epidemiology\/number-of-people-with-ms. Accessed 8 Dec 2025"},{"key":"10286_CR178","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1177\/1352458512473189","volume":"19","author":"A Nuyts","year":"2013","unstructured":"Nuyts A, Lee W, Bashir-Dar R et al (2013) Dendritic cells in multiple sclerosis: key players in the immunopathogenesis, key players for new cellular immunotherapies? Mult Scler 19:995\u20131002. https:\/\/doi.org\/10.1177\/1352458512473189","journal-title":"Mult Scler"},{"key":"10286_CR179","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","volume":"365","author":"P O\u2019Connor","year":"2011","unstructured":"O\u2019Connor P, Wolinsky JS, Confavreux C et al (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365:1293\u20131303. https:\/\/doi.org\/10.1056\/NEJMoa1014656","journal-title":"N Engl J Med"},{"key":"10286_CR180","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1172\/JCI13032","volume":"108","author":"JK Olson","year":"2001","unstructured":"Olson JK, Croxford JL, Calenoff MA et al (2001) A virus-induced molecular mimicry model of multiple sclerosis. J Clin Invest 108:311\u2013318. https:\/\/doi.org\/10.1172\/JCI13032","journal-title":"J Clin Invest"},{"key":"10286_CR181","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","volume":"13","author":"T Olsson","year":"2017","unstructured":"Olsson T, Barcellos LF, Alfredsson L (2017) Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol 13:25\u201336. https:\/\/doi.org\/10.1038\/nrneurol.2016.187","journal-title":"Nat Rev Neurol"},{"key":"10286_CR182","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109225","author":"AE Oppong","year":"2024","unstructured":"Oppong AE, Coelewij L, Robertson G et al (2024) Blood metabolomic and transcriptomic signatures stratify patient subgroups in multiple sclerosis according to disease severity. iScience. https:\/\/doi.org\/10.1016\/j.isci.2024.109225","journal-title":"iScience"},{"key":"10286_CR183","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/j.1471-4159.2010.07136.x","volume":"116","author":"MK Paintlia","year":"2011","unstructured":"Paintlia MK, Paintlia AS, Singh AK, Singh I (2011) Synergistic activity of interleukin-17 and tumor necrosis factor-\u03b1 enhances oxidative stress-mediated oligodendrocyte apoptosis. J Neurochem 116:508\u2013521. https:\/\/doi.org\/10.1111\/j.1471-4159.2010.07136.x","journal-title":"J Neurochem"},{"key":"10286_CR184","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1080\/07391102.2019.1567384","volume":"38","author":"P Pandey","year":"2020","unstructured":"Pandey P, Roy KK, Doerksen RJ (2020) Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist. J Biomol Struct Dyn 38:32\u201347. https:\/\/doi.org\/10.1080\/07391102.2019.1567384","journal-title":"J Biomol Struct Dyn"},{"key":"10286_CR185","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3390\/cimb45020094","volume":"45","author":"G Papiri","year":"2023","unstructured":"Papiri G, D\u2019Andreamatteo G, Cacchi\u00f2 G et al (2023) Multiple Sclerosis: inflammatory and neuroglial aspects. Curr Issues Mol Biol 45:1443\u20131470. https:\/\/doi.org\/10.3390\/cimb45020094","journal-title":"Curr Issues Mol Biol"},{"key":"10286_CR186","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1007\/s00415-017-8594-9","volume":"264","author":"G Pardo","year":"2017","unstructured":"Pardo G, Jones DE (2017) The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol 264:2351\u20132374. https:\/\/doi.org\/10.1007\/s00415-017-8594-9","journal-title":"J Neurol"},{"key":"10286_CR187","doi-asserted-by":"publisher","first-page":"e0231483","DOI":"10.1371\/journal.pone.0231483","volume":"15","author":"C Parravicini","year":"2020","unstructured":"Parravicini C, Lecca D, Marangon D et al (2020) Development of the first in vivo GPR17 ligand through an iterative drug discovery pipeline: A novel disease-modifying strategy for multiple sclerosis. PLoS ONE 15:e0231483. https:\/\/doi.org\/10.1371\/journal.pone.0231483","journal-title":"PLoS ONE"},{"key":"10286_CR188","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1093\/brain\/awl217","volume":"129","author":"P Patrikios","year":"2006","unstructured":"Patrikios P, Stadelmann C, Kutzelnigg A et al (2006) Remyelination is extensive in a subset of multiple sclerosis patients. Brain 129:3165\u20133172. https:\/\/doi.org\/10.1093\/brain\/awl217","journal-title":"Brain"},{"key":"10286_CR189","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.720694","author":"J Peng","year":"2021","unstructured":"Peng J, Jury EC, D\u00f6nnes P, Ciurtin C (2021) Machine learning techniques for personalised medicine approaches in immune-mediated chronic inflammatory diseases: applications and challenges. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2021.720694","journal-title":"Front Pharmacol"},{"key":"10286_CR190","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/joim.13215","volume":"289","author":"F Piehl","year":"2021","unstructured":"Piehl F (2021) Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis. J Intern Med 289:771\u2013791. https:\/\/doi.org\/10.1111\/joim.13215","journal-title":"J Intern Med"},{"key":"10286_CR191","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/ana.24286","volume":"76","author":"T Plavina","year":"2014","unstructured":"Plavina T, Subramanyam M, Bloomgren G et al (2014) Anti\u2013JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76:802\u2013812. https:\/\/doi.org\/10.1002\/ana.24286","journal-title":"Ann Neurol"},{"key":"10286_CR192","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899\u2013910. https:\/\/doi.org\/10.1056\/NEJMoa044397","journal-title":"N Engl J Med"},{"key":"10286_CR193","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA et al (2019) Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 18:41\u201358. https:\/\/doi.org\/10.1038\/nrd.2018.168","journal-title":"Nat Rev Drug Discov"},{"key":"10286_CR194","doi-asserted-by":"publisher","first-page":"108769","DOI":"10.1016\/j.intimp.2022.108769","volume":"108","author":"W-H Qi","year":"2022","unstructured":"Qi W-H, Zhang Y-Y, Xing K et al (2022) 2\u2032, 4\u2032-Dihydroxy-2,3-dimethoxychalcone: A pharmacological inverse agonist of ROR\u03b3t ameliorating Th17-driven inflammatory diseases by regulating Th17\/Treg. Int Immunopharmacol 108:108769\u2013108769. https:\/\/doi.org\/10.1016\/j.intimp.2022.108769","journal-title":"Int Immunopharmacol"},{"key":"10286_CR195","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26136286","author":"Z Qiao","year":"2025","unstructured":"Qiao Z, Wang Y, Ma X et al (2025) GPX1 and RCN1 as new endoplasmic reticulum stress-related biomarkers in multiple sclerosis brain tissue and their involvement in the APP-CD74 pathway: an integrated study combining machine learning and multi-omics. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26136286","journal-title":"Int J Mol Sci"},{"key":"10286_CR196","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.667705","author":"M Radandish","year":"2021","unstructured":"Radandish M, Khalilian P, Esmaeil N (2021) The role of distinct subsets of macrophages in the pathogenesis of MS and the impact of different therapeutic agents on these populations. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2021.667705","journal-title":"Front Immunol"},{"issue":"1","key":"10286_CR197","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40169-017-0181-2","volume":"7","author":"RR Ramsay","year":"2018","unstructured":"Ramsay RR, Popovic-Nikolic MR, Nikolic K et al (2018) A perspective on multi-target drug discovery and design for complex diseases. Clin Transl Med 7:3. https:\/\/doi.org\/10.1186\/s40169-017-0181-2","journal-title":"Clin Transl Med"},{"key":"10286_CR198","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/nn.4338","volume":"19","author":"RM Ransohoff","year":"2016","unstructured":"Ransohoff RM (2016) A polarizing question: do M1 and M2 microglia exist? Nat Neurosci 19:987\u2013991. https:\/\/doi.org\/10.1038\/nn.4338","journal-title":"Nat Neurosci"},{"key":"10286_CR199","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nri3265","volume":"12","author":"RM Ransohoff","year":"2012","unstructured":"Ransohoff RM, Engelhardt B (2012) The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol 12:623\u2013635. https:\/\/doi.org\/10.1038\/nri3265","journal-title":"Nat Rev Immunol"},{"key":"10286_CR200","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105614","volume":"86","author":"S Rasouli","year":"2024","unstructured":"Rasouli S, Dakkali MS, Azarbad R et al (2024) Predicting the conversion from clinically isolated syndrome to multiple sclerosis: an explainable machine learning approach. Mult Scler Relat Disord 86:105614. https:\/\/doi.org\/10.1016\/j.msard.2024.105614","journal-title":"Mult Scler Relat Disord"},{"key":"10286_CR201","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","volume":"20","author":"DS Reich","year":"2021","unstructured":"Reich DS, Arnold DL, Vermersch P et al (2021) Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol 20:729\u2013738. https:\/\/doi.org\/10.1016\/S1474-4422(21)00237-4","journal-title":"Lancet Neurol"},{"key":"10286_CR202","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-025-09254-2","volume":"26","author":"G Riboni-Verri","year":"2025","unstructured":"Riboni-Verri G, McMurran CE, Mukherjee T et al (2025) The Cambridge Centre for Myelin Repair trial Two (CCMR Two): a trial protocol for a phase 2a, randomised, double-blind, placebo-controlled clinical trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapy. Trials 26:562. https:\/\/doi.org\/10.1186\/s13063-025-09254-2","journal-title":"Trials"},{"key":"10286_CR203","doi-asserted-by":"publisher","first-page":"16414","DOI":"10.3390\/ijms160716414","volume":"16","author":"T Ruck","year":"2015","unstructured":"Ruck T, Bittner S, Wiendl H, Meuth SG (2015) Alemtuzumab in multiple sclerosis: mechanism of action and beyond. Int J Mol Sci 16:16414\u201316439. https:\/\/doi.org\/10.3390\/ijms160716414","journal-title":"Int J Mol Sci"},{"key":"10286_CR204","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA et al (2006) Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis. N Engl J Med 354:911\u2013923. https:\/\/doi.org\/10.1056\/NEJMoa044396","journal-title":"N Engl J Med"},{"key":"10286_CR205","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.70038","volume":"86","author":"R Rushendran","year":"2025","unstructured":"Rushendran R, Singh SA, Begum RF et al (2025) Bioinformatics exploration of the therapeutic potential of Lotus seed compounds in multiple sclerosis: a network analysis of c-Jun pathway. Drug Dev Res 86:e70038. https:\/\/doi.org\/10.1002\/ddr.70038","journal-title":"Drug Dev Res"},{"key":"10286_CR206","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.nicl.2017.11.015","volume":"17","author":"M Salem","year":"2018","unstructured":"Salem M, Cabezas M, Valverde S et al (2018) A supervised framework with intensity subtraction and deformation field features for the detection of new T2-w lesions in multiple sclerosis. NeuroImage: Clin 17:607\u2013615. https:\/\/doi.org\/10.1016\/j.nicl.2017.11.015","journal-title":"NeuroImage: Clin"},{"key":"10286_CR207","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2016.03.014","volume":"166\u2013167","author":"M Salou","year":"2016","unstructured":"Salou M, Nicol B, Garcia A et al (2016) Neuropathologic, phenotypic and functional analyses of Mucosal Associated Invariant T cells in Multiple Sclerosis. Clin Immunol 166\u2013167:1\u201311. https:\/\/doi.org\/10.1016\/j.clim.2016.03.014","journal-title":"Clin Immunol"},{"key":"10286_CR208","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1002\/hbm.24687","volume":"40","author":"L Sander","year":"2019","unstructured":"Sander L, Pezold S, Andermatt S et al (2019) Accurate, rapid and reliable, fully automated MRI brainstem segmentation for application in multiple sclerosis and neurodegenerative diseases. Hum Brain Mapp 40:4091\u20134104. https:\/\/doi.org\/10.1002\/hbm.24687","journal-title":"Hum Brain Mapp"},{"key":"10286_CR209","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104622","volume":"73","author":"E Sardari","year":"2023","unstructured":"Sardari E, Ebadi A, Razzaghi-Asl N (2023) In silico repurposing of CNS drugs for multiple sclerosis. Mult Scler Relat Disord 73:104622. https:\/\/doi.org\/10.1016\/j.msard.2023.104622","journal-title":"Mult Scler Relat Disord"},{"key":"10286_CR210","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1002\/eji.201344214","volume":"44","author":"K Sathiyanadan","year":"2014","unstructured":"Sathiyanadan K, Coisne C, Enzmann G et al (2014) PSGL-1 and E\/P-selectins are essential for T-cell rolling in inflamed CNS microvessels but dispensable for initiation of EAE. Eur J Immunol 44:2287\u20132294. https:\/\/doi.org\/10.1002\/eji.201344214","journal-title":"Eur J Immunol"},{"key":"10286_CR211","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2567.2010.03360.x","volume":"131","author":"N Schleinitz","year":"2010","unstructured":"Schleinitz N, V\u00e9ly F, Harl\u00e9 J-R, Vivier E (2010) Natural killer cells in human autoimmune diseases. Immunology 131:451\u2013458. https:\/\/doi.org\/10.1111\/j.1365-2567.2010.03360.x","journal-title":"Immunology"},{"key":"10286_CR212","doi-asserted-by":"publisher","first-page":"170ra15","DOI":"10.1126\/scitranslmed.3004970","volume":"5","author":"A Schneider","year":"2013","unstructured":"Schneider A, Long SA, Cerosaletti K et al (2013) In Active Relapsing-Remitting Multiple Sclerosis, Effector T Cell Resistance to Adaptive Tregs Involves IL-6\u2013Mediated Signaling. Sci Transl Med 5:170ra15\u2013170ra15. https:\/\/doi.org\/10.1126\/scitranslmed.3004970","journal-title":"Sci Transl Med"},{"key":"10286_CR213","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.autrev.2007.02.003","volume":"6","author":"W Schrempf","year":"2007","unstructured":"Schrempf W, Ziemssen T (2007) Glatiramer acetate: mechanisms of action in multiple sclerosis. Autoimmun Rev 6:469\u2013475. https:\/\/doi.org\/10.1016\/j.autrev.2007.02.003","journal-title":"Autoimmun Rev"},{"key":"10286_CR214","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1750-3639.2004.tb00049.x","volume":"14","author":"B Serafini","year":"2004","unstructured":"Serafini B, Rosicarelli B, Magliozzi R et al (2004) Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14:164\u2013174. https:\/\/doi.org\/10.1111\/j.1750-3639.2004.tb00049.x","journal-title":"Brain Pathol"},{"key":"10286_CR215","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.145327","volume":"319","author":"S Shariati","year":"2025","unstructured":"Shariati S, Mafakher L, Shirani M, Baradaran M (2025) Unveiling new Kv1.3 channel blockers from scorpion venom: characterization of Meuk7-3 and in silico design of its analogs for enhanced affinity and therapeutic potential. Int J Biol Macromol 319:145327. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.145327","journal-title":"Int J Biol Macromol"},{"key":"10286_CR216","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nature12979","volume":"507","author":"P Shen","year":"2014","unstructured":"Shen P, Roch T, Lampropoulou V et al (2014) IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 507:366\u2013370. https:\/\/doi.org\/10.1038\/nature12979","journal-title":"Nature"},{"key":"10286_CR217","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.ydbio.2005.03.020","volume":"282","author":"T Shimizu","year":"2005","unstructured":"Shimizu T, Kagawa T, Wada T et al (2005) Wnt signaling controls the timing of oligodendrocyte development in the spinal cord. Dev Biol 282:397\u2013410. https:\/\/doi.org\/10.1016\/j.ydbio.2005.03.020","journal-title":"Dev Biol"},{"key":"10286_CR218","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/imr.12170","volume":"259","author":"KS Smigiel","year":"2014","unstructured":"Smigiel KS, Srivastava S, Stolley JM, Campbell DJ (2014) Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation. Immunol Rev 259:40\u201359. https:\/\/doi.org\/10.1111\/imr.12170","journal-title":"Immunol Rev"},{"key":"10286_CR219","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.neuron.2014.11.006","volume":"84","author":"CD Sorbara","year":"2014","unstructured":"Sorbara CD, Wagner NE, Ladwig A et al (2014) Pervasive Axonal Transport Deficits in Multiple Sclerosis Models. Neuron 84:1183\u20131190. https:\/\/doi.org\/10.1016\/j.neuron.2014.11.006","journal-title":"Neuron"},{"key":"10286_CR220","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1212\/WNL.0000000000000125","volume":"82","author":"PS Sorensen","year":"2014","unstructured":"Sorensen PS, Lisby S, Grove R et al (2014) Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis. Neurology 82:573\u2013581. https:\/\/doi.org\/10.1212\/WNL.0000000000000125","journal-title":"Neurology"},{"key":"10286_CR221","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJMoa2201904","volume":"387","author":"L Steinman","year":"2022","unstructured":"Steinman L, Fox E, Hartung H-P et al (2022) Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. N Engl J Med 387:704\u2013714. https:\/\/doi.org\/10.1056\/NEJMoa2201904","journal-title":"N Engl J Med"},{"key":"10286_CR222","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.899340","author":"X Sun","year":"2022","unstructured":"Sun X, Ren X, Zhang J et al (2022) Discovering miRNAs associated with multiple sclerosis based on network representation learning and deep learning methods. Front Genet. https:\/\/doi.org\/10.3389\/fgene.2022.899340","journal-title":"Front Genet"},{"key":"10286_CR223","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095753","volume":"9","author":"EM Sweeney","year":"2014","unstructured":"Sweeney EM, Vogelstein JT, Cuzzocreo JL et al (2014) A Comparison of Supervised Machine Learning Algorithms and Feature Vectors for MS Lesion Segmentation Using Multimodal Structural MRI. PLoS One 9:e95753. https:\/\/doi.org\/10.1371\/journal.pone.0095753","journal-title":"PLoS One"},{"key":"10286_CR224","doi-asserted-by":"crossref","unstructured":"Tan C, Sun F, Kong T et al (2018) A Survey on Deep Transfer Learning. pp 270\u2013279","DOI":"10.1007\/978-3-030-01424-7_27"},{"key":"10286_CR225","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/ana.24201","volume":"76","author":"V Tepav\u010devi\u0107","year":"2014","unstructured":"Tepav\u010devi\u0107 V, Kerninon C, Aigrot MS et al (2014) Early netrin-1 expression impairs central nervous system remyelination. Ann Neurol 76:252\u2013268. https:\/\/doi.org\/10.1002\/ana.24201","journal-title":"Ann Neurol"},{"key":"10286_CR226","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/ni.3731","volume":"18","author":"AN Theofilopoulos","year":"2017","unstructured":"Theofilopoulos AN, Kono DH, Baccala R (2017) The multiple pathways to autoimmunity. Nat Immunol 18:716\u2013724. https:\/\/doi.org\/10.1038\/ni.3731","journal-title":"Nat Immunol"},{"key":"10286_CR227","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1080\/1062936X.2024.2431486","volume":"35","author":"M Torabi","year":"2024","unstructured":"Torabi M, Haririan I, Foroumadi A et al (2024a) A deep learning model based on the BERT pre-trained model to predict the antiproliferative activity of anti-cancer chemical compounds. SAR QSAR Environ Res 35:971\u2013992. https:\/\/doi.org\/10.1080\/1062936X.2024.2431486","journal-title":"SAR QSAR Environ Res"},{"key":"10286_CR228","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.176176","volume":"963","author":"M Torabi","year":"2024","unstructured":"Torabi M, Yasami-Khiabani S, Sardari S et al (2024b) Identification of new potential candidates to inhibit EGF via machine learning algorithm. Eur J Pharmacol 963:176176. https:\/\/doi.org\/10.1016\/j.ejphar.2023.176176","journal-title":"Eur J Pharmacol"},{"key":"10286_CR229","doi-asserted-by":"publisher","first-page":"31536","DOI":"10.1038\/s41598-025-14699-1","volume":"15","author":"M Torabi","year":"2025","unstructured":"Torabi M, Mojtabavi S, Mahdavi M et al (2025a) Integrating data augmentation and BERT-based deep learning for predicting alpha-glucosidase inhibitors derived from Black Cohosh. Sci Rep 15:31536. https:\/\/doi.org\/10.1038\/s41598-025-14699-1","journal-title":"Sci Rep"},{"key":"10286_CR230","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1007\/s11030-025-11214-6","volume":"29","author":"M Torabi","year":"2025","unstructured":"Torabi M, Sardari S, Rodr\u00edguez-Mart\u00ednez A et al (2025b) Drug repurposing to identify potential FDA-approved drugs targeting three main angiogenesis receptors through a deep learning framework. Mol Divers 29:3637\u20133659. https:\/\/doi.org\/10.1007\/s11030-025-11214-6","journal-title":"Mol Divers"},{"key":"10286_CR231","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev.neuro.30.051606.094313","volume":"31","author":"BD Trapp","year":"2008","unstructured":"Trapp BD, Nave K-A (2008) Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 31:247\u2013269. https:\/\/doi.org\/10.1146\/annurev.neuro.30.051606.094313","journal-title":"Annu Rev Neurosci"},{"key":"10286_CR232","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/S1474-4422(09)70043-2","volume":"8","author":"BD Trapp","year":"2009","unstructured":"Trapp BD, Stys PK (2009) Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 8:280\u2013291. https:\/\/doi.org\/10.1016\/S1474-4422(09)70043-2","journal-title":"Lancet Neurol"},{"key":"10286_CR233","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/00365513.2017.1303843","volume":"77","author":"AG Trenova","year":"2017","unstructured":"Trenova AG, Slavov GS, Manova MG et al (2017) Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis. Scand J Clin Lab Invest 77:283\u2013288. https:\/\/doi.org\/10.1080\/00365513.2017.1303843","journal-title":"Scand J Clin Lab Invest"},{"key":"10286_CR234","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41573-019-0024-5","volume":"18","author":"J Vamathevan","year":"2019","unstructured":"Vamathevan J, Clark D, Czodrowski P et al (2019) Applications of machine learning in drug discovery and development. Nat Rev Drug Discov 18:463\u2013477. https:\/\/doi.org\/10.1038\/s41573-019-0024-5","journal-title":"Nat Rev Drug Discov"},{"key":"10286_CR235","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10994-019-05855-6","volume":"109","author":"JE van Engelen","year":"2020","unstructured":"van Engelen JE, Hoos HH (2020) A survey on semi-supervised learning. Mach Learn 109:373\u2013440. https:\/\/doi.org\/10.1007\/s10994-019-05855-6","journal-title":"Mach Learn"},{"key":"10286_CR236","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1177\/1060028013509232","volume":"47","author":"JV Venci","year":"2013","unstructured":"Venci JV, Gandhi MA (2013) Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis. Ann Pharmacother 47:1697\u20131702. https:\/\/doi.org\/10.1177\/1060028013509232","journal-title":"Ann Pharmacother"},{"key":"10286_CR237","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1212\/WNL.0b013e3181c97f5a","volume":"74","author":"T Vollmer","year":"2010","unstructured":"Vollmer T, Stewart T, Baxter N (2010) Mitoxantrone and cytotoxic drugs\u2019 mechanisms of action. Neurology 74:S41\u2013S46. https:\/\/doi.org\/10.1212\/WNL.0b013e3181c97f5a","journal-title":"Neurology"},{"key":"10286_CR238","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/475158","volume":"2015","author":"E Volpe","year":"2015","unstructured":"Volpe E, Battistini L, Borsellino G (2015) Advances in T helper 17 cell biology: pathogenic role and potential therapy in multiple sclerosis. Mediators Inflamm 2015:475158. https:\/\/doi.org\/10.1155\/2015\/475158","journal-title":"Mediators Inflamm"},{"key":"10286_CR239","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/brain\/awy301","volume":"142","author":"MR von Essen","year":"2019","unstructured":"von Essen MR, Ammitzb\u00f8ll C, Hansen RH et al (2019) Proinflammatory CD20\u2009+\u2009T cells in the pathogenesis of multiple sclerosis. Brain 142:120\u2013132. https:\/\/doi.org\/10.1093\/brain\/awy301","journal-title":"Brain"},{"key":"10286_CR240","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L et al (2020) Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler J 26:1816\u20131821. https:\/\/doi.org\/10.1177\/1352458520970841","journal-title":"Mult Scler J"},{"key":"10286_CR241","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3390\/e20040254","volume":"20","author":"S-H Wang","year":"2018","unstructured":"Wang S-H, Cheng H, Phillips P, Zhang Y-D (2018) Multiple sclerosis identification based on fractional Fourier entropy and a modified Jaya algorithm. Entropy 20:254. https:\/\/doi.org\/10.3390\/e20040254","journal-title":"Entropy"},{"key":"10286_CR242","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.bbadis.2010.06.009","volume":"1812","author":"MS Weber","year":"2011","unstructured":"Weber MS, Hemmer B, Cepok S (2011) The role of antibodies in multiple sclerosis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1812:239\u2013245. https:\/\/doi.org\/10.1016\/j.bbadis.2010.06.009","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"key":"10286_CR243","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01454","author":"ANR Weber","year":"2017","unstructured":"Weber ANR, Bittner Z, Liu X et al (2017) Bruton\u2019s tyrosine kinase: an emerging key player in innate immunity. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2017.01454","journal-title":"Front Immunol"},{"key":"10286_CR244","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nrneurol.2013.95","volume":"9","author":"H Wiendl","year":"2013","unstructured":"Wiendl H, Gross CC (2013) Modulation of IL-2R\u03b1 with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol 9:394\u2013404. https:\/\/doi.org\/10.1038\/nrneurol.2013.95","journal-title":"Nat Rev Neurol"},{"key":"10286_CR245","doi-asserted-by":"crossref","unstructured":"Wu GF, Cross AH (2021) Immunology of Multiple Sclerosis. In: Piquet AL, Alvarez E (eds) Neuroimmunology: Multiple Sclerosis, Autoimmune Neurology and Related Diseases. Springer International Publishing, Cham, pp 117\u2013135","DOI":"10.1007\/978-3-030-61883-4_9"},{"key":"10286_CR246","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102335","volume":"45","author":"D Wynn","year":"2020","unstructured":"Wynn D, Lategan TW, Sprague TN et al (2020) Monomethyl fumarate has better gastrointestinal tolerability profile compared with dimethyl fumarate. Mult Scler Relat Disord 45:102335. https:\/\/doi.org\/10.1016\/j.msard.2020.102335","journal-title":"Mult Scler Relat Disord"},{"key":"10286_CR247","doi-asserted-by":"publisher","first-page":"151790","DOI":"10.1016\/j.bbrc.2025.151790","volume":"763","author":"J Xie","year":"2025","unstructured":"Xie J, Wu M, Li L et al (2025) Integrated bioinformatics and experimental verification to dissect the mechanisms and bioactive ingredients of Radix Rehmanniae in treating multiple sclerosis. Biochem Biophys Res Commun 763:151790. https:\/\/doi.org\/10.1016\/j.bbrc.2025.151790","journal-title":"Biochem Biophys Res Commun"},{"key":"10286_CR248","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1038\/s41591-025-03743-2","volume":"31","author":"Z Xu","year":"2025","unstructured":"Xu Z, Ren F, Wang P et al (2025) A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. Nat Med 31:2602\u20132610. https:\/\/doi.org\/10.1038\/s41591-025-03743-2","journal-title":"Nat Med"},{"key":"10286_CR249","doi-asserted-by":"publisher","first-page":"315","DOI":"10.4103\/1735-5362.343085","volume":"17","author":"S Yahyazadeh","year":"2022","unstructured":"Yahyazadeh S, Esmaeil N, Shaygannejad V, Mirmosayyeb O (2022) Comparison of follicular T helper cells, monocytes, and T cells priming between newly diagnosed and rituximab-treated MS patients and healthy controls. Res Pharm Sci 17:315. https:\/\/doi.org\/10.4103\/1735-5362.343085","journal-title":"Res Pharm Sci"},{"key":"10286_CR250","doi-asserted-by":"publisher","first-page":"10520","DOI":"10.1021\/acs.chemrev.8b00728","volume":"119","author":"X Yang","year":"2019","unstructured":"Yang X, Wang Y, Byrne R et al (2019) Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery. Chem Rev 119:10520\u201310594. https:\/\/doi.org\/10.1021\/acs.chemrev.8b00728","journal-title":"Chem Rev"},{"key":"10286_CR251","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1021\/acschemneuro.1c00011","volume":"12","author":"J Yang","year":"2021","unstructured":"Yang J, Li H, Wang F et al (2021) Network-based target prioritization and drug candidate identification for multiple sclerosis: from analyzing \u201comics data\u201d to druggability simulations. ACS Chem Neurosci 12:917\u2013929. https:\/\/doi.org\/10.1021\/acschemneuro.1c00011","journal-title":"ACS Chem Neurosci"},{"key":"10286_CR252","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23115877","author":"J Yang","year":"2022","unstructured":"Yang J, Hamade M, Wu Q et al (2022) Current and future biomarkers in multiple sclerosis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23115877","journal-title":"Int J Mol Sci"},{"key":"10286_CR253","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18061215","volume":"18","author":"M-P Yannakakis","year":"2017","unstructured":"Yannakakis M-P, Simal C, Tzoupis H et al (2017) Design and synthesis of non-peptide mimetics mapping the immunodominant myelin basic protein (MBP83\u201396) epitope to function as T-cell receptor antagonists. Int J Mol Sci 18:1215. https:\/\/doi.org\/10.3390\/ijms18061215","journal-title":"Int J Mol Sci"},{"key":"10286_CR254","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/356063a0","volume":"356","author":"TA Yednock","year":"1992","unstructured":"Yednock TA, Cannon C, Fritz LC et al (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against \u03b14\u03b2l integrin. Nature 356:63\u201366. https:\/\/doi.org\/10.1038\/356063a0","journal-title":"Nature"},{"key":"10286_CR255","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.nicl.2017.10.015","volume":"17","author":"Y Yoo","year":"2018","unstructured":"Yoo Y, Tang LYW, Brosch T et al (2018) Deep learning of joint myelin and T1w MRI features in normal-appearing brain tissue to distinguish between multiple sclerosis patients and healthy controls. NeuroImage: Clin 17:169\u2013178. https:\/\/doi.org\/10.1016\/j.nicl.2017.10.015","journal-title":"NeuroImage: Clin"},{"key":"10286_CR256","doi-asserted-by":"publisher","first-page":"6543","DOI":"10.1007\/s00415-024-12651-3","volume":"271","author":"H Yousef","year":"2024","unstructured":"Yousef H, Malagurski Tortei B, Castiglione F (2024) Predicting multiple sclerosis disease progression and outcomes with machine learning and MRI-based biomarkers: a review. J Neurol 271:6543\u20136572. https:\/\/doi.org\/10.1007\/s00415-024-12651-3","journal-title":"J Neurol"},{"key":"10286_CR257","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1006\/exnr.1998.7002","volume":"155","author":"Z Yu","year":"1999","unstructured":"Yu Z, Luo H, Fu W, Mattson MP (1999) The endoplasmic reticulum stress-responsive protein GRP78 protects neurons against excitotoxicity and apoptosis: suppression of oxidative stress and stabilization of calcium homeostasis. Exp Neurol 155:302\u2013314. https:\/\/doi.org\/10.1006\/exnr.1998.7002","journal-title":"Exp Neurol"},{"key":"10286_CR258","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj6187","volume":"9","author":"D Zhai","year":"2023","unstructured":"Zhai D, Yan S, Samsom J et al (2023) Small-molecule targeting AMPA-mediated excitotoxicity has therapeutic effects in mouse models for multiple sclerosis. Sci Adv 9:eadj6187. https:\/\/doi.org\/10.1126\/sciadv.adj6187","journal-title":"Sci Adv"},{"key":"10286_CR259","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jocs.2018.07.003","volume":"28","author":"Y-D Zhang","year":"2018","unstructured":"Zhang Y-D, Pan C, Sun J, Tang C (2018) Multiple sclerosis identification by convolutional neural network with dropout and parametric ReLU. J Comput Sci 28:1\u201310. https:\/\/doi.org\/10.1016\/j.jocs.2018.07.003","journal-title":"J Comput Sci"},{"key":"10286_CR260","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.3390\/ijms24076373","volume":"24","author":"X Zhao","year":"2023","unstructured":"Zhao X, Jacob C (2023) Mechanisms of demyelination and remyelination strategies for multiple sclerosis. Int J Mol Sci 24:6373. https:\/\/doi.org\/10.3390\/ijms24076373","journal-title":"Int J Mol Sci"},{"key":"10286_CR261","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad300","volume":"6","author":"W Zhu","year":"2024","unstructured":"Zhu W, Chen C, Zhang L et al (2024) Association between serum multi-protein biomarker profile and real-world disability in multiple sclerosis. Brain Commun 6:fcad300. https:\/\/doi.org\/10.1093\/braincomms\/fcad300","journal-title":"Brain Commun"},{"key":"10286_CR262","doi-asserted-by":"publisher","first-page":"8463","DOI":"10.1073\/pnas.1820039116","volume":"116","author":"I Zubizarreta","year":"2019","unstructured":"Zubizarreta I, Fl\u00f3rez-Grau G, Vila G et al (2019) Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. Proc Natl Acad Sci 116:8463\u20138470. https:\/\/doi.org\/10.1073\/pnas.1820039116","journal-title":"Proc Natl Acad Sci"}],"container-title":["Journal of Neuroimmune Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-026-10286-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11481-026-10286-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-026-10286-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:59:41Z","timestamp":1776059981000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11481-026-10286-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":262,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10286"],"URL":"https:\/\/doi.org\/10.1007\/s11481-026-10286-x","relation":{},"ISSN":["1557-1904"],"issn-type":[{"value":"1557-1904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that all scientific content, research concepts, analyses, and interpretations presented in this manuscript were conceived and developed independently, without the use of artificial intelligence language model for the generation of original scientific material. The sole application of AI in this work was limited to language editing at the final stage, utilizing the ChatGPT engine (OpenAI, GPT-5 model). This editorial assistance did not impact the scientific integrity or substantive content of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of AI Use"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}